samedan logo
 
 
spacer
home > pmps > spring 2004 > clever coding meets the pharma challenge
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Clever Coding Meets the Pharma Challenge

The pharmaceutical sector is a multi-million pound business for suppliers of coding and marking solutions. However by its very nature it is an industry which presents many specific challenges. In this article, we examine the coding and marking issues that have to be addressed and talk about some of the solutions on offer.

The pharmaceutical industry is perhaps one of the most demanding areas when it comes to coding and marking. It is heavily regulated to ensure that products are clearly and accurately coded with traceability and end consumer information. Pharmaceutical companies are regularly and rigorously audited to ensure compliance with Food and Drug Administration (FDA) rules. In addition, they face a continuing rise in counterfeit drugs. Against this backdrop, pharmaceutical manufacturers look to suppliers of coding and marking equipment to provide solutions which not only meet their requirements today, but will remain in step with the developing needs of this sector.

The Challenges

The decision to purchase coding and marking systems is largely driven by legislation. FDA laws, which apply internationally in order to provide end user safety, require the use of traceability codes to track products back to their original production batch. This enables swift action to be taken in the event that a recall of a batch of drugs is necessary. Codes such as use by dates are also a key requirement.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Charles Randon, Senior Product Manager at Linx Printing Technologies

Charles Randon is a Product Manager at Linx Printing Technologies plc. He has been with the company for four years and is responsible for the commercial management of Linx's range of ink jet printers. A recent focus for Charles has been the launch of the new Linx 4900 two-line ink jet printer.
spacer
Charles Randon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials

Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement